新利luck18展位#43

第46届韩国非临床试验钻研会 (The Korean Society of Nonclinical Study, KSNS) 将于2024年10月17-18日在韩国庆尚南路进行。本次大会由韩国非临床试验钻研协会（KSNS）组织，是韩国最负盛名和最具影响力的非临床钻研会议之一。届时来自生物医药技术领域研发公司的辅导者和决策者，及多多非临床钻研专家们都将参与这次活动。TFM of Medicilon Chuansha Site邹汉军博士DABT将携带新利luck18美国团队出席这次大会，我们在展位#43，等待与您的互换！

功夫 | October 17-18, 2024
地址 | Gyeongju, South Gyeongsang Province
新利luck18展位  | 43，不见不散！

作为国内较早为客户提供临床前动物尝试的CRO公司之一，新利luck18具备全面的临床前钻研服务能力，可能提供系统的体内药效学和GLP前提下的药代动力学、安全性评价钻研服务。目前新利luck18已占有多种不变的药效评价模型，可对细胞毒及靶向类幼分子、单抗及双特异抗体等大分子药物、ADC、CAR-T/CAR-NK细胞医治抗肿瘤新药提供全面系统的评价。新利luck18对大量化学药物和生物药物成立了系统分析步骤和体内表评价步骤，蕴含幼分子和大分子生物分析平台、免疫分析工作站及放射性同位素药代动力学钻研平台等，支持早期筛选、成药性评价和IND申报等。新利luck18占有经中国NMPA认证的GLP资质，且通过了美国FDA的GLP现场查抄，具备切合国际尺度的GLP系统，并且获得AAALAC认证，尝试动物治理质量尺度获得国际认可。至2024年6月底，新利luck18已为全球超2000家客户提供药物研发服务，参加研发实现的新药及仿造药项目已有490件IND获批临床，与国内表优质客户共同成长。

KSNS现场新利luck18专家

邹汉军博士 TFM of Medicilon Chuansha Site

Dr. Hanjun Zou is currently the Testing Facility Management for Medicilon Chuansha site in Shanghai. Dr. Zou joined Medicilon in March 2023 as Senior Director in which he led the team or as the study director to be responsible for the overall planning and implementation of the nonclinical study programs, including but not limited to the IND/NDA package design, selection of species, dose determination, protocol design, results interpretation, report drafting and communication with regulatory agencies. The type of drugs he supported included small molecule chemicals, peptide, fusion protein, oligonucleotide, single/bispecific antibodies, ADC, CGT product etc. Before joining Medicilon, Dr. Zou has more than 16 years of experience in toxicity and preclinical safety assessment with most career working in multinational companies. Dr. Zou is also a certified toxicologist (DCST, ERT & DABT) in China, Europe and the United States.

新利luck18非临床钻研服务

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones. Medicilon's Preclinical Research Division services include the following for small molecules, biologics and medicinal herbs: Pharmacology, Pharmacodynamics, ADME, DMPK, Bioanalysis, Drug Safety Evaluation. Medicilon maintains a large in-house library of animal disease models to meet the research demands in different therapeutic areas.  Medicilon can also assist clients in the preparation of a preclinical safety evaluation package.

Pharmacology 

?Tumor Animal Models (400+) 
?Non-tumor Animal Models (270+)

DMPK & Bioanalysis

?In Vitro ADMET 
?In Vivo PK & Tox

Preclinical Safety Assessment (GLP & non-GLP) 

?Single and repeated-dose toxicity studies
 ?Reproductive/developmental and juvenile toxicity studies
 ?Genotoxicity studies
 ?Toxicokinetic studies
 ?Safety pharmacology research
 ?Immunogenicity studies
 ?Local tolerance studies
 ?Carcinogenicity studies

预约商务洽谈